Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO’s Growth Momentum Strong
HONG KONG, Mar 25, 2025 – (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (Stock Code: 688185.SH, 6185.HK, “CanSinoBIO” or the “Company”), a leading player in China’s vaccine industry, achieved significant revenue growth in 2024, driven by continuous R&D innovation and strong commercial capabilities.In 2024, CanSinoBIO reported a total revenue of RMB 846 million, marking a 137.01% year-on-year increase. This remarkable growth signifies the initial success of the company’s transformation from a Biotech to a Biopharma company. With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape, CanSinoBIO is poised for continuous growth momentum in 2025.In 2024, CanSinoBIO’s core product, the MCV4 (Menhycia®, the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197)), the only quadrivalent meningococcal conjugate vaccine in China, has rapidly achieved market penetration under its unique “direct sales + CSO” d…